Low-dose naltrexone, an opioid-receptor antagonist, is a broad-spectrum analgesic: a retrospective cohort study

Pain Manag
15 March 2022
https://pubmed.ncbi.nlm.nih.gov/35289682/

Aim: To evaluate the use of low-dose naltrexone (LDN) as a broad-spectrum analgesic.

The state-of-the-art pharmacotherapeutic options for the treatment of chronic non-cancer pain

Expert Opin Pharmacother
04 April 2022
https://pubmed.ncbi.nlm.nih.gov/35354341/

Pharmacist Michelle Moser, LDN Key to Success (LDN, low dose naltrexone)

Nonopioid Analgesic, Nonpharmacologic Options for Pain Management Reviewed

Drug Topics
24 March 2022
https://www.drugtopics.com/view/nonopioid-analgesic-nonpharmacologic-options-for-pain-management-reviewed

Newer Drugs for Rheumatoid Arthritis All Have Similar Risks — Maybe It’s Time to Go Natural?

Verve Times
15 March 2022
https://vervetimes.com/newer-drugs-for-rheumatoid-arthritis-all-have-similar-risks-maybe-its-time-to-go-natural/

Dry eye research reveals impact of disease, potential new treatments

Healia Optometry
10 March 2022
https://www.healio.com/news/optometry/20220310/dry-eye-research-reveals…

Dr Sajad Zalzala, LDN Radio Show February 2022 (LDN, low dose naltrexone)

Monika - US: Relapsing Polychondritis (LDN, low dose naltrexone)

An LDN Research Trust Radio show with Linda Elsegood and Monika from the US talks about her experience of LDN (Low Dose Naltrexone for Relapsing Polychondritis which is a rare condition.

Topical Therapeutic Options in Corneal Neuropathic Pain  (Abstract)

Front Pharmacol
31 January 2022
https://pubmed.ncbi.nlm.nih.gov/35173607/